BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies
9. June 2022 – Walder Wyss advises BioVersys in connection with the CHF 24.2m Series C Financing.
BioVersys, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced today that it has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies; BioVersys intends to complete the Series C investment round by the end of 2022.
The proceed will be used to initiate first Phase II clinical trials of BV100 and BVL-GSK098 and the preclinical development of BV200.
The Walder Wyss team includes Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Robert von Rosen (Partner, Corporate/M&A and Venture Capital), (Karina Tschon (Associate, Corporate/M&A and Venture Capital) as well as Lucas Maurer (Associate, Corporate/M&A and Venture Capital).